NetWorth
LeaderPortfolio
Giuliani
G
Rank #1981
SWITZERLAND•Healthcare•Pharmaceuticals

Giammaria Giuliani

Net Worth
$2.087B
-0.96% (24h)
Giammaria Giuliani is a Swiss healthcare investor with an estimated net worth of $1.9 billion. His wealth stems primarily from investments in the pharmaceutical industry. Giuliani is known for his 5% stake in Royalty Pharma, the world's largest acquirer of pharmaceutical royalties, and also holds stakes in HBM Healthcare Investments and several biotech firms. Giuliani's career includes executive roles at Giuliani SpA and board positions in various pharmaceutical and biotech companies, where he participates in shaping investment strategies. Additionally, Giuliani is involved in philanthropy through the Giuliani Foundation, supporting education, health, and economic well-being.

How to read Giammaria Giuliani's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Giammaria Giuliani, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.087B alongside global rank #1981, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (SWITZERLAND) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Giammaria Giuliani, born February 20, 1978, embarked on his career in 2002 at Leo Burnett (Publicis Group). In 2004, he took on the role of Executive Vice President and Head of Research and Development at Giuliani SpA, a family pharmaceutical company founded in 1889 in Milan, Italy.

Rise to Success

Since 2014, Giuliani has been an active healthcare investor. His investment portfolio includes a 5% stake in Royalty Pharma, the world’s largest acquirer of pharmaceutical royalties. Royalty Pharma went public in 2020 and has generated revenue from blockbuster drugs. Giuliani and his brother also own stakes in HBM Healthcare Investments and other biotech companies. He is a Brown University trustee, and is part of the take private of Rothschild & Co.

Key Business Strategies

Giuliani's investment strategy focuses on the pharmaceutical sector, particularly on acquiring royalties and supporting biotech firms. He is involved in defining investment strategies for companies he serves on the board, making sure they align with their missions and values. He also develops and finances medical and scientific research projects, most notably through the Giuliani Foundation.

Philanthropy

Giuliani is dedicated to philanthropic efforts through the Giuliani Foundation, which supports education, health, and economic well-being in developing countries. The Giuliani Foundation also funds research into medical conditions. In August 2023, the Giuliani Foundation established the Giammaria and Sabrina Giuliani Endowed Faculty Support Fund at the Ragon Institute to support research in human health and the immune system.

Career Timeline

2014

Healthcare Investor

Began holding board positions in pharmaceutical and biotech companies, defining investment strategies and supporting research.

2004

Executive Vice President and Head of R&D at Giuliani SpA

Assumed the role of Executive Vice President and Head of Research and Development at the family's pharmaceutical company, Giuliani SpA.

2002

Began Career at Leo Burnett

Started professional career at Leo Burnett (Publicis Group).

Philanthropic Impact

PhilanthropyUnknown

Giuliani Foundation

Supports education, health, and economic well-being in developing countries.

PhilanthropyUnknown

Ragon Institute Endowed Faculty Support Fund

Established the Giammaria and Sabrina Giuliani Endowed Faculty Support Fund to support research in human health and the immune system.

Key Business Ventures & Holdings

CompanyStakeValue
Royalty Pharma5.00%—

Net Worth History

In-Depth Analysis

Early Life

Giammaria Giuliani, born February 20, 1978, embarked on his career in 2002 at Leo Burnett (Publicis Group). In 2004, he took on the role of Executive Vice President and Head of Research and Development at Giuliani SpA, a family pharmaceutical company founded in 1889 in Milan, Italy.

Rise to Success

Since 2014, Giuliani has been an active healthcare investor. His investment portfolio includes a 5% stake in Royalty Pharma, the world’s largest acquirer of pharmaceutical royalties. Royalty Pharma went public in 2020 and has generated revenue from blockbuster drugs. Giuliani and his brother also own stakes in HBM Healthcare Investments and other biotech companies. He is a Brown University trustee, and is part of the take private of Rothschild & Co.

Key Business Strategies

Giuliani's investment strategy focuses on the pharmaceutical sector, particularly on acquiring royalties and supporting biotech firms. He is involved in defining investment strategies for companies he serves on the board, making sure they align with their missions and values. He also develops and finances medical and scientific research projects, most notably through the Giuliani Foundation.

Philanthropy

Giuliani is dedicated to philanthropic efforts through the Giuliani Foundation, which supports education, health, and economic well-being in developing countries. The Giuliani Foundation also funds research into medical conditions. In August 2023, the Giuliani Foundation established the Giammaria and Sabrina Giuliani Endowed Faculty Support Fund at the Ragon Institute to support research in human health and the immune system.

Data Sources & Methodology

Figures for Giammaria Giuliani are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom